Clene
NASDAQ: CLNNSalt Lake City, US · Founded 2020 · Delaware corporation · 1 known investors
Find your way into Clene
120 people in our graph can introduce you to the Clene team.
Sign up to see every warm intro you have to Clene
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Clene team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Clene is a clinical-stage biopharmaceutical company developing nanotherapeutics that target cellular energy impairments to treat neurodegenerative diseases and restore neuronal health. Its platform produces clean-surfaced, catalytically-active nanocrystals for therapeutic use.
Founders & leadership
Clene was founded in 2020 by Mark Mortenson and Reed N. Wilcox.

Board
Investors · 1
Reported raises · per SEC filings
Form D private placements$16.6M disclosed across 2 of 4 rounds · 2018–2026
▶$7.3MraisedOct 2024 · 13 investors · PharmaceuticalsRule 506(b)
- Alison MoscaDirector
- Mark MortensonExecutive Officer
- Robert Dee EtheringtonExecutive Officer, Director
- Shalom JacobovitzDirector
- Morgan BrownExecutive Officer
- David MatlinDirector
- Jonathon T. GayDirector
- Reed Neil WilcoxDirector
- Vallerie V. McLaughlinDirector
- Matthew KiernanDirector
- Arjun DesaiDirector
- Offering amount
- $7.3M
- Amount sold
- $7.3M
- Sales commissions
- $436.6K
- Placement agents
- Canaccord Genuity LLC
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$9.3MraisedMay 2021 · 8 investors · PharmaceuticalsRule 506(b)
- Alison MoscaDirector
- David MatlinDirector
- Robert GlanzmanExecutive Officer
- Tae Heum JeongExecutive Officer
- Shalom JacobovitzDirector
- Reed WilcoxDirector
- Chidozie UgwumbaDirector
- Fiona CostelloDirector
- Jonathon GayDirector
- Robert EtheringtonExecutive Officer, Director
- John StevensDirector
- Mark MortensonExecutive Officer
- Offering amount
- $9.3M
- Amount sold
- $9.3M
- First sale
- May 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 8
Companies working in the same space as Clene.
Frequently asked questions
- What does Clene do?
- Clene is a clinical-stage biopharmaceutical company developing nanotherapeutics that target cellular energy impairments to treat neurodegenerative diseases and restore neuronal health. Its platform produces clean-surfaced, catalytically-active nanocrystals for therapeutic use.
- Who founded Clene?
- Clene was founded by Mark Mortenson, Reed N. Wilcox in 2020.
- Who are Clene's investors?
- Clene's investors include SymBiosis.
- How much funding has Clene raised?
- Clene has disclosed $16.6M raised across 2 of its 4 known rounds.
- Where is Clene headquartered?
- Clene is headquartered in Salt Lake City, US.







